Last updated: September 1, 2026
GLPG3970 is an oral, selective SIK2/3 inhibitor developed by Galapagos NV for immune-mediated inflammatory diseases. Its clinical development was discontinued after the program failed to generate sufficient efficacy in Phase 2 studies, including ulcerative colitis and psoriasis. GLPG3970 has no FDA approval, no commercial sales, no Orange Book listing, and no credible near-term market opportunity. Its current commercial value is effectively zero unless Galapagos or a third party revives the molecule for a new indication.
What is GLPG3970 and how does it work?
GLPG3970 is a small-molecule inhibitor of salt-inducible kinases 2 and 3, or SIK2/3. Galapagos investigated the compound as an oral anti-inflammatory therapy for diseases driven by dysregulated immune signaling.
The program was designed to address conditions including:
- Ulcerative colitis
- Plaque psoriasis
- Potentially other immune-mediated inflammatory diseases
SIK2 and SIK3 regulate macrophage and dendritic-cell signaling, cytokine production, and immune-cell activation. The mechanism was differentiated from established therapies targeting TNF, IL-17, IL-23, JAK, and other inflammatory pathways.
GLPG3970 was not a biologic. It was an orally administered small molecule, so a successful product could have competed on administration convenience and manufacturing cost against injectable biologics.
What is the current development status of GLPG3970?
GLPG3970 is a discontinued clinical-stage program. Galapagos stopped further development after Phase 2 efficacy results did not support progression.
| Development attribute |
Status |
| Sponsor |
Galapagos NV |
| Drug type |
Oral small molecule |
| Target |
SIK2/3 |
| Lead indications |
Ulcerative colitis and psoriasis |
| Highest disclosed stage |
Phase 2 |
| FDA approval |
None |
| Commercial launch |
None |
| Current clinical development |
Discontinued |
| Orange Book status |
No listed product |
| Biosimilar exposure |
None |
| Generic exposure |
No marketed product to challenge |
Galapagos’ public pipeline disclosures subsequently focused on other assets, including GLPG3667, a TYK2 inhibitor, and later-stage cell therapies. GLPG3970 was removed from active development following the company’s review of the clinical data.[1]
What happened in the GLPG3970 ulcerative colitis trial?
The principal setback came from the Phase 2b DIVERSITY program in ulcerative colitis. The study evaluated GLPG3970 in patients with active disease who had inadequate response or intolerance to existing treatments.
The DIVERSITY study was designed to assess clinical activity during induction treatment. Public disclosures indicated that GLPG3970 did not produce the level of efficacy required to support further development. Galapagos consequently discontinued the program rather than advancing it into Phase 3.
The failure was commercially important because ulcerative colitis was the larger and more valuable target market for the asset. A positive result could have positioned GLPG3970 against oral JAK inhibitors, S1P modulators, biologics, and emerging IL-23 therapies.
Ulcerative colitis competitive context
The relevant competitive products included:
- AbbVie’s Rinvoq, an oral JAK inhibitor
- Pfizer’s Xeljanz, an oral JAK inhibitor
- Bristol Myers Squibb’s Zeposia, an oral S1P receptor modulator
- Takeda’s Entyvio, a gut-selective biologic
- Johnson & Johnson’s Stelara, an IL-12/IL-23 biologic
- AbbVie’s Skyrizi, an IL-23 inhibitor
- Anti-TNF products, including Humira and Remicade
A new oral mechanism would have required clear efficacy, a strong safety profile, and a differentiated label. The Phase 2 data did not establish that profile.
What happened in the GLPG3970 psoriasis program?
Galapagos also studied GLPG3970 in plaque psoriasis. The psoriasis program did not provide sufficient evidence for continued investment.
Psoriasis is a highly competitive market in which IL-17 and IL-23 inhibitors have set a high efficacy standard. Oral competitors include deucravacitinib, apremilast, and JAK-pathway candidates under development.
For GLPG3970 to advance, the drug would have needed to demonstrate a clinically meaningful psoriasis response, a favorable safety profile, and a commercial advantage over established biologics and oral agents. The disclosed Phase 2 experience did not justify Phase 3 investment.
When did GLPG3970 lose development exclusivity?
GLPG3970 did not lose exclusivity through generic entry. The more important event was clinical discontinuation.
No FDA-approved GLPG3970 product exists, so the standard commercial exclusivity framework for an approved drug does not apply. There is no:
- New Chemical Entity exclusivity period
- New Clinical Investigation exclusivity period
- Pediatric exclusivity period
- Orange Book patent term linked to an approved product
- Commercial generic launch date
Any patents covering GLPG3970 may remain legally active depending on filing dates, patent-term adjustments, jurisdictions, claim scope, maintenance, and terminal disclaimers. Those rights have limited economic value without a viable product or licensee.
What is the Orange Book status of GLPG3970?
GLPG3970 has no Orange Book listing.
The FDA Orange Book lists approved drug products and associated patents or exclusivity information submitted by sponsors. Because GLPG3970 was never approved, it has no FDA reference-listed drug status and cannot be the subject of an ANDA Paragraph IV challenge against an approved product.
This means:
| Regulatory issue |
GLPG3970 status |
| NDA approval |
None |
| Reference-listed drug |
None |
| Orange Book listing |
None |
| ANDA challenge |
None |
| Paragraph IV litigation |
None identified |
| FDA market exclusivity |
None |
| Approved indication |
None |
Are there Paragraph IV challenges or patent lawsuits involving GLPG3970?
No material Paragraph IV litigation is associated with GLPG3970 because the compound never reached FDA approval.
Paragraph IV litigation generally arises when a generic applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. GLPG3970 has no approved reference product and no Orange Book-listed patent dispute of that type.
Patent disputes involving Galapagos or other drugs in inflammatory disease do not automatically affect GLPG3970. The relevant risk would instead involve pre-launch patent infringement, licensing disputes, ownership claims, or challenges to composition-of-matter and use patents. No major publicly disclosed litigation appears to have created a commercial pathway for GLPG3970.
What patents protect GLPG3970?
Galapagos likely pursued patent protection for the compound, related chemical entities, pharmaceutical compositions, and therapeutic uses. The most commercially important rights would have been:
- Composition-of-matter claims covering GLPG3970 or related molecules.
- Solid-state, salt, polymorph, or formulation claims.
- Method-of-use claims for inflammatory diseases.
- Manufacturing and intermediate claims.
- Combination-treatment claims.
The value of these rights has declined sharply because the clinical program was discontinued. Composition-of-matter protection would have been the strongest category, while method-of-use and formulation claims would have faced narrower commercial relevance.
There is no approved product against which patent expiry can be measured for market-entry purposes. Any surviving patent term would protect a noncommercial development asset rather than an active revenue stream.
What formulation patents protect GLPG3970?
GLPG3970 was developed as an oral small molecule. Public development disclosures do not indicate an approved extended-release, delayed-release, injectable, or device-based formulation.
Potential formulation protection could have covered:
- Oral tablets or capsules
- Specific crystalline forms
- Salt forms
- Excipient combinations
- Stability-enhancing formulations
- Dose regimens
These rights would have been secondary to composition-of-matter protection. No formulation has reached commercial regulatory status.
Does GLPG3970 face biosimilar or generic competition?
GLPG3970 faces neither active biosimilar nor generic competition.
Biosimilars apply to biologic reference products. GLPG3970 is a small molecule, so a future competitor would use an abbreviated generic pathway rather than a biosimilar pathway. However, no ANDA-based market entry is possible today because no GLPG3970 reference product has been approved.
If the asset were revived and approved, generic risk would depend on:
- Remaining composition-of-matter patent life
- Validity of formulation and use patents
- Regulatory exclusivity
- The approved label
- Whether a generic could enter with a carve-out indication
- Clinical and manufacturing complexity
How strong is the GLPG3970 patent estate?
The patent estate has low current commercial strength despite potentially meaningful historical protection.
| Patent-estate factor |
Assessment |
| Composition-of-matter value |
Potentially strong if valid and unexpired |
| Method-of-use value |
Limited after failed clinical development |
| Formulation value |
Unclear and commercially secondary |
| Manufacturing value |
Potential barrier if process-specific |
| Litigation leverage |
Low without an approved product |
| Licensing value |
Low unless new efficacy is demonstrated |
| Generic deterrence |
None currently required |
| Overall commercial strength |
Weak in present form |
The principal weakness is not necessarily patent validity. It is the absence of a viable clinical and regulatory asset. A broad patent cannot create market value if efficacy is unproven and the sponsor has abandoned development.
Could GLPG3970 be revived or licensed?
A revival is possible in principle but commercially unlikely without new data.
A third party would need to establish a differentiated rationale, such as:
- A biomarker-defined responder population
- A new inflammatory indication
- Combination use with an approved therapy
- A reformulated product with improved exposure
- Evidence that prior trials selected the wrong dose or patient population
The licensing case is weak because the molecule failed to establish adequate proof of concept in its principal indications. A buyer would also face development costs, regulatory risk, patent-term erosion, and competition from highly effective approved therapies.
No significant licensing transaction for GLPG3970 has been publicly disclosed. Galapagos’ major strategic transaction with Gilead concerned other assets and did not create a commercial development pathway for GLPG3970.[2]
What is the market projection for GLPG3970?
The base-case market projection is zero.
| Scenario |
Probability assessment |
Commercial outcome |
| Continued development by Galapagos |
Very low |
No meaningful revenue |
| Out-license to a major pharmaceutical company |
Low |
Possible restart, but no near-term sales |
| Academic or investigator-led repositioning |
Low |
No material commercial impact |
| New indication with positive proof of concept |
Very low but nonzero |
Potential redevelopment value |
| Approval and launch |
Remote |
Long-dated, uncertain revenue |
| Generic entry |
Not applicable today |
No current market |
A conventional peak-sales forecast is not supportable because the program lacks active clinical development, a regulatory filing, an approved indication, and a launch plan.
Indicative valuation framework
GLPG3970 should be valued as a discontinued preclinical or clinical option, not as a late-stage pipeline asset. Its current value would be based on:
- Patent survival
- Ability to obtain or generate new clinical data
- Availability of manufacturing material
- Strength of the SIK2/3 biological rationale
- Cost of restarting development
- Competitive intensity in the selected indication
The probability-adjusted value is likely minimal compared with active Phase 2 or Phase 3 assets. Any material valuation would require evidence of renewed sponsor interest or new clinical efficacy.
How does GLPG3970 compare with competing inflammatory drugs?
| Drug |
Target or pathway |
Modality |
Regulatory position |
Competitive position versus GLPG3970 |
| GLPG3970 |
SIK2/3 |
Oral small molecule |
Discontinued, not approved |
No current position |
| Rinvoq |
JAK1 |
Oral small molecule |
Approved in multiple inflammatory diseases |
Strong efficacy and commercial presence |
| Sotyktu |
TYK2 |
Oral small molecule |
Approved for plaque psoriasis |
Directly relevant oral immunology competitor |
| Skyrizi |
IL-23 |
Biologic |
Approved in psoriasis and inflammatory bowel disease |
Strong efficacy and expanding label |
| Entyvio |
Integrin |
Biologic |
Approved in ulcerative colitis and Crohn’s disease |
Established safety and disease specialization |
| Zeposia |
S1P |
Oral small molecule |
Approved in ulcerative colitis |
Oral-market competitor |
| Otezla |
PDE4 |
Oral small molecule |
Approved in psoriasis and psoriatic arthritis |
Established oral option |
GLPG3970’s potential differentiation was its novel mechanism and oral delivery. Those advantages were insufficient without demonstrated clinical efficacy.
Key Takeaways
- GLPG3970 is an oral SIK2/3 inhibitor developed by Galapagos.
- The program reached Phase 2 in ulcerative colitis and psoriasis.
- Galapagos discontinued development after inadequate clinical results.
- GLPG3970 has no FDA approval, NDA, Orange Book listing, or commercial sales.
- No Paragraph IV litigation or generic challenge is relevant today.
- Biosimilar competition does not apply because GLPG3970 is a small molecule.
- Patent rights may remain in some jurisdictions, but their commercial value is limited.
- No material licensing transaction has revived the program.
- The base-case market projection is zero.
- Any future value depends on a new indication, new efficacy data, or a third-party development program.
FAQs About GLPG3970
Is GLPG3970 still in clinical trials?
No. The publicly disclosed development program was discontinued after Phase 2 evaluation in inflammatory diseases.
What company developed GLPG3970?
Galapagos NV developed GLPG3970. The compound was part of the company’s immunology pipeline.
Could GLPG3970 become a treatment for ulcerative colitis?
Only through a substantial redevelopment program supported by new efficacy data. The existing Phase 2 results did not support progression.
Is GLPG3970 a TYK2 inhibitor like Sotyktu?
No. GLPG3970 targets SIK2 and SIK3. Sotyktu targets TYK2.
What is the expected launch date for GLPG3970?
There is no expected launch date. The compound has not been approved and has no active commercial development plan.
References
- Galapagos NV. (2022). Annual report 2021. Galapagos NV.
- Galapagos NV. (2024). Annual report 2023. Galapagos NV.
- U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Studies of GLPG3970 in inflammatory diseases. ClinicalTrials.gov.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
